Sudhanshu Mulay, MD
Assistant ProfessorDownloadHi-Res Photo
About
Copy Link
Titles
Assistant Professor
Director, Anticoagulation Program , Classical Hematology Program
Biography
Sudhanshu Mulay, MD, is an Assistant Professor of Medicine (Medical Oncology and Hematology) and cares for patients with a wide range of benign hematologic disorders at Smilow Cancer Hospital at Waterbury. Conditions he treats include, but are not limited to, thrombosis, anemia, bleeding and platelet disorders, and other hematological conditions and rare diseases.
Dr. Mulay received his medical degree from BJ Medical College in Pune, India. He completed his residency at the University of Connecticut School of Medicine and two fellowships; one in hematology/oncology at the University of Connecticut School of Medicine, and one in transfusion medicine at the Mayo Clinic.
Prior to joining Yale, Dr. Mulay was the Medical Director for the Anticoagulation Service at Saint Francis Hospital in Hartford. In 2023, he received the Outstanding Physician Award from Lea’s Foundation for Leukemia Research. The award recognizes a physician who provides compassionate patient care and outstanding leadership in building a world-class hematology program. His research interests are in thrombosis and anticoagulation management.
Last Updated on March 05, 2025.
Appointments
Medical Oncology and Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- Hematology
- Internal Medicine
- Medical Oncology and Hematology
- Yale Cancer Center
- Yale Medicine
- Yale New Haven Health System
Education & Training
- MS
- Centro de Estudios Biosanitarios,, Molecular Oncology (2017)
- Fellowship
- University of Connecticut (2014)
- Fellowship
- Mayo Clinic (2011)
- Residency
- University of Connecticut (2010)
- Internship
- Michael Reese Hospital (2008)
- MD
- BJ Medical College (2004)
Advanced Training & Certifications
- Certificate of Advanced Studies in Antithrombotic Management
- Maastricht University (2024)
Research
Copy Link
Overview
Thrombosis and anticoagulation management.
ORCID
0000-0001-5467-1043
Research at a Glance
Publications Timeline
A big-picture view of Sudhanshu Mulay's research output by year.
9Publications
177Citations
Publications
2025
Impact of Anemia Management on Bleeding Outcomes in Anticoagulated Patients: A Retrospective Cohort Analysis.
Godin SL, Hanna C, Naut E, Mulay S. Impact of Anemia Management on Bleeding Outcomes in Anticoagulated Patients: A Retrospective Cohort Analysis. Clin Hematol Int 2025, 7: 34-45. PMID: 40443840, DOI: 10.46989/001c.138102.Peer-Reviewed Original Research
2020
Bortezomib-induced motor neuropathy: A case report.
Singh M, Thomas VM, Mulay S. Bortezomib-induced motor neuropathy: A case report. J Oncol Pharm Pract 2020, 26: 1549-1552. PMID: 32054409, DOI: 10.1177/1078155220904153.Peer-Reviewed Original Research
2014
Reversing the Effects of Antiplatelet Agents in the Setting of Intracranial Hemorrhage
Jaben E, Mulay S, Stubbs J. Reversing the Effects of Antiplatelet Agents in the Setting of Intracranial Hemorrhage. Journal Of Intensive Care Medicine 2014, 30: 3-7. PMID: 25492811, DOI: 10.1177/0885066613487298.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsOutcomes of plasma exchange in patients with transplant‐associated thrombotic microangiopathy based on time of presentation since transplant
Mulay S, Kreuter J, Bryant S, Elliott M, Hogan W, Winters J, Gastineau D. Outcomes of plasma exchange in patients with transplant‐associated thrombotic microangiopathy based on time of presentation since transplant. Journal Of Clinical Apheresis 2014, 30: 147-153. PMID: 25230249, DOI: 10.1002/jca.21352.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsADAM ProteinsADAMTS13 ProteinAdultAgedFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedPlasma ExchangePlatelet CountProspective StudiesPurpura, Thrombotic ThrombocytopenicRetrospective StudiesThrombotic MicroangiopathiesTransplantationTreatment OutcomeYoung AdultConceptsTransplant-associated thrombotic microangiopathyEfficacy of PEPlasma exchangeTime of presentationThrombotic microangiopathyBetter outcomesLarge single-institution seriesDay 100 mortalityTA-TMA patientsRare clinical syndromeCause mortality ratesSingle-institution seriesTiming of presentationClinical improvementRetrospective studyClinical syndromeInstitution seriesSingle institutionComplete resolutionMortality ratePatientsDay 30Overall efficacyTransplantationSignificant mortalityRecurrent and partially reversible cardiomyopathy occurring during treatment with bendamustine and rituximab
Mulay S, Boruchov A. Recurrent and partially reversible cardiomyopathy occurring during treatment with bendamustine and rituximab. Leukemia & Lymphoma 2014, 56: 805-807. PMID: 24913498, DOI: 10.3109/10428194.2014.931954.Peer-Reviewed Original ResearchCitationsInfusion technique of hematopoietic progenitor cells and related adverse events (CME)
Mulay S, Greiner C, Mohr A, Bryant S, Lingineni R, Padley D, Hogan W, Gastineau D, Jacob E. Infusion technique of hematopoietic progenitor cells and related adverse events (CME). Transfusion 2014, 54: 1997-2003. PMID: 24697759, DOI: 10.1111/trf.12572.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAcetaminophenAdolescentAdultAgedBlood PreservationChildChild, PreschoolCryopreservationCryoprotective AgentsDimethyl SulfoxideDiphenhydramineFlushingFurosemideHematologic NeoplasmsHumansHydrocortisoneHypertensionInfantInfant, NewbornInfusions, IntravenousIsotonic SolutionsMiddle AgedNauseaNeutrophilsPeripheral Blood Stem Cell TransplantationPremedicationRetrospective StudiesRisk FactorsSyringesYoung AdultConceptsInfusion-related adverse eventsAdverse eventsHPC infusionSingle-institution retrospective analysisHematopoietic progenitor cell transplantPeripheral blood HPCsIndependent risk factorProgenitor cell transplantInfusion techniqueWhite blood cellsDifferent infusion techniquesCell transplantRisk factorsRetrospective analysisPolymorphonuclear leukocytesInfusionPatientsStudy designBlood cellsStudy periodManual pushCommon typeHPC productsAid of gravityFirst study
2012
Risks and adverse outcomes associated with emergency‐release red blood cell transfusion
Mulay S, Jaben E, Johnson P, Badjie K, Stubbs J. Risks and adverse outcomes associated with emergency‐release red blood cell transfusion. Transfusion 2012, 53: 1416-1420. PMID: 23067326, DOI: 10.1111/j.1537-2995.2012.03922.x.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsEmergency-release transfusionHemolytic transfusion reactionsTransfusion reactionsAcute hemolytic transfusion reactionRBC unitsAntibody specificityAcute adverse outcomesAdditional RBC transfusionsAntibody screen resultsRate of alloimmunizationRed blood cell unitsPositive antibody screenSerologic transfusion reactionsMultiple antibody specificitiesRisk of alloimmunizationRBC transfusionIncompatible transfusionsAdverse outcomesAntibody screenEmergency transfusionPatientsMedicine DatabaseTransfusionSingle antibody specificityAntibody identification
2010
Successful resolution of acute myelogenous leukemia-associated hemophagocytic lymphohistiocytosis with decitabine
Mulay S, Bauer F, Boruchov A, Bilgrami S. Successful resolution of acute myelogenous leukemia-associated hemophagocytic lymphohistiocytosis with decitabine. Leukemia & Lymphoma 2010, 52: 341-343. PMID: 21142783, DOI: 10.3109/10428194.2010.534209.Peer-Reviewed Original ResearchCitationsAltmetricA Proteasome Inhibitor, Bortezomib, Inhibits Breast Cancer Growth and Reduces Osteolysis by Downregulating Metastatic Genes
Jones M, Liu J, Barthel T, Hussain S, Lovria E, Cheng D, Schoonmaker J, Mulay S, Ayers D, Bouxsein M, Stein G, Mukherjee S, Lian J. A Proteasome Inhibitor, Bortezomib, Inhibits Breast Cancer Growth and Reduces Osteolysis by Downregulating Metastatic Genes. Clinical Cancer Research 2010, 16: 4978-4989. PMID: 20843837, PMCID: PMC2955762, DOI: 10.1158/1078-0432.ccr-09-3293.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsAntineoplastic AgentsBoronic AcidsBortezomibBreast NeoplasmsCell Growth ProcessesCell Line, TumorDown-RegulationFemaleFluorodeoxyglucose F18Gene Expression Regulation, NeoplasticHumansMiceMice, SCIDNeoplasm MetastasisOsteolysisPositron-Emission TomographyProtease InhibitorsPyrazinesRadiopharmaceuticalsXenograft Model Antitumor AssaysConceptsTumor growthTumor cellsInhibits breast cancer growthAdvanced breast cancerMetastatic bone diseaseProteasome inhibitorsBone tumor growthBreast cancer growthTibia of miceInhibits tumor growthInhibited cell proliferationPositron emission tomographyExpression of factorsBone osteolysisBone metastasesOsteolytic lesionsTreatment regimensMultiple myelomaOsteolytic diseasesBortezomib treatmentBreast cancerBone diseaseBone microenvironmentBrCa cellsCancer growth
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
IRB ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
IRB ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026Recruiting ParticipantsDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
IRB ID2000025737RoleSub InvestigatorPrimary Completion Date12/31/2029Recruiting ParticipantsEffective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
IRB ID2000029969RoleSub InvestigatorPrimary Completion Date12/31/2027Recruiting Participants
Clinical Care
Copy Link
Overview
Sudhanshu Mulay, MD, is a hematologist who specializes in diagnosing and treating patients with a variety of benign blood conditions such as thrombosis, anemia, bleeding and platelet disorders, and rare diseases.
As an adjunct assistant professor at Yale School of Medicine, Dr. Mulay is involved in research in thrombosis and anticoagulation management.
Dr. Mulay received his medical training from BJ Medical College in India, completed residencies in internal medicine at Michael Reese Hospital in Chicago and at the University of Connecticut School of Medicine. He pursued fellowships in hematology/oncology at the University of Connecticut School of Medicine and transfusion medicine at the Mayo Clinic.
Clinical Specialties
Hematology
Board Certifications
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2014
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2014
Blood Banking Transfusion Medicine
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2011
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2010
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Copy Link
Get In Touch
Copy Link
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.